{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T22:50:59Z","timestamp":1792363859262,"version":"4.4.0"},"reference-count":113,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.cmi.2025.06.003","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T02:10:57Z","timestamp":1749435057000},"page":"1647-1654","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Fungal infections in patients with haematological malignancies in the pre-triazole era: the dawn of a new era in medical mycology"],"prefix":"10.1016","volume":"31","author":[{"given":"Umut","family":"Akova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Hicklen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell E.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios P.","family":"Kontoyiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2025.06.003_bib1","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/jac\/dkp074","article-title":"The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Fever and neutropenia: The early years","volume":"63","author":"Bodey","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.06.003_bib2","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJM194806032382301","article-title":"Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid","volume":"238","author":"Farber","year":"1948","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2025.06.003_bib3","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/B978-1-4831-9930-6.50011-3","article-title":"Progress and perspectives in the chemotherapy of acute leukemia","volume":"2","author":"Frei","year":"1965","journal-title":"Adv Chemother"},{"key":"10.1016\/j.cmi.2025.06.003_bib4","first-page":"1284","article-title":"Approaches to improving the chemotherapy of Hodgkin\u2019s disease","volume":"26","author":"Frei","year":"1966","journal-title":"Cancer Res"},{"key":"10.1016\/j.cmi.2025.06.003_bib5","doi-asserted-by":"crossref","first-page":"328","DOI":"10.7326\/0003-4819-64-2-328","article-title":"Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia","volume":"64","author":"Bodey","year":"1966","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cmi.2025.06.003_bib6","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM196205032661802","article-title":"The quantitative relation between platelet count and hemorrhage in patients with acute leukemia","volume":"266","author":"Gaydos","year":"1962","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2025.06.003_bib7","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1001\/jama.1967.03130120031008","article-title":"Acute leukemia and infection","volume":"201","author":"Viola","year":"1967","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2025.06.003_bib8","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1056\/NEJM197105132841904","article-title":"Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia","volume":"284","author":"Schimpff","year":"1971","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2025.06.003_bib9","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1542\/peds.18.4.595","article-title":"Candida infections in children with neoplastic disease; influence of therapy with antibiotics and steroid hormones","volume":"18","author":"Foley","year":"1956","journal-title":"Pediatrics"},{"key":"10.1016\/j.cmi.2025.06.003_bib10","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/0021-9681(66)90066-X","article-title":"Fungal infections complicating acute leukemia","volume":"19","author":"Bodey","year":"1966","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.cmi.2025.06.003_bib11","doi-asserted-by":"crossref","first-page":"4","DOI":"10.7326\/0003-4819-90-1-4","article-title":"Invasive aspergillosis in acute leukemia: Correlation with nose cultures and antibiotic use","volume":"90","author":"Aisner","year":"1979","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cmi.2025.06.003_bib12","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1001\/jama.1976.03260300037029","article-title":"Aspergillus infections in cancer patients. Association with fireproofing materials in a new hospital","volume":"235","author":"Aisner","year":"1976","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2025.06.003_bib13","first-page":"10","article-title":"Fungal infections in bone marrow transplant patients","volume":"17","author":"Meyers","year":"1990","journal-title":"Semin Oncol"},{"key":"10.1016\/j.cmi.2025.06.003_bib14","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1001\/jama.1992.03490050055025","article-title":"Changing trends in allogeneic bone marrow transplantation for leukemia in the 1980s","volume":"268","author":"Bortin","year":"1992","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2025.06.003_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1470-9465.2004.00841.x","article-title":"History of the development of azole derivatives","volume":"10","author":"Maertens","year":"2004","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.06.003_bib16","doi-asserted-by":"crossref","first-page":"805","DOI":"10.4065\/mcp.2011.0247","article-title":"Current concepts in antifungal pharmacology","volume":"86","author":"Lewis","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cmi.2025.06.003_bib17","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S1473-3099(05)70297-8","article-title":"Posaconazole: A broad-spectrum triazole antifungal","volume":"5","author":"Torres","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.cmi.2025.06.003_bib18","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2217\/fmb.15.34","article-title":"Isavuconazole: A new extended spectrum triazole for invasive mold diseases","volume":"10","author":"Ananda-Rajah","year":"2015","journal-title":"Future Microbiol"},{"key":"10.1016\/j.cmi.2025.06.003_bib19","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1093\/jac\/dkf045","article-title":"Echinocandins: A new class of antifungal","volume":"49","author":"Denning","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.06.003_bib20","doi-asserted-by":"crossref","first-page":"S604","DOI":"10.1093\/cid\/civ814","article-title":"Echinocandins: The expanding antifungal armamentarium","volume":"61","author":"Aguilar-Zapata","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.06.003_bib21","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.1093\/clinids\/22.Supplement_2.S133","article-title":"Lipid formulations of amphotericin B: Recent progress and future directions","volume":"22","author":"Hiemenz","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.06.003_bib22","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/mmy\/myw114","article-title":"Invasive aspergillosis in acute myeloid leukemia: Are we making progress in reducing mortality?","volume":"55","author":"Dragonetti","year":"2017","journal-title":"Med Mycol"},{"key":"10.1016\/j.cmi.2025.06.003_bib23","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2025.06.003_bib24","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/1097-0142(197208)30:2<348::AID-CNCR2820300207>3.0.CO;2-O","article-title":"Fungal infection in acute leukemia","volume":"30","author":"Mirsky","year":"1972","journal-title":"Cancer."},{"key":"10.1016\/j.cmi.2025.06.003_bib25","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1001\/archinte.1947.00220160002001","article-title":"Aspergillosis and the aspergilli; report of a unique case of the disease","volume":"80","author":"Cawley","year":"1947","journal-title":"Arch Intern Med (Chic)"},{"key":"10.1016\/j.cmi.2025.06.003_bib26","first-page":"601","article-title":"The development of disseminated visceral mycosis during therapy for acute leukemia","volume":"29","author":"Craig","year":"1953","journal-title":"Am J Pathol"},{"key":"10.1016\/j.cmi.2025.06.003_bib27","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/1097-0142(196908)24:2<417::AID-CNCR2820240226>3.0.CO;2-2","article-title":"Hypersplenism due to disseminated candidiasis in a patient with acute leukemia","volume":"24","author":"Bodey","year":"1969","journal-title":"Cancer"},{"key":"10.1016\/j.cmi.2025.06.003_bib28","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/S0022-3476(73)80543-8","article-title":"Fusarium solani infection during treatment for acute leukemia","volume":"83","author":"Cho","year":"1973","journal-title":"J Pediatr"},{"key":"10.1016\/j.cmi.2025.06.003_bib29","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1002\/1097-0142(197509)36:3<1106::AID-CNCR2820360340>3.0.CO;2-Z","article-title":"Trichosporon sepsis and leukemia","volume":"36","author":"Rivera","year":"1975","journal-title":"Cancer."},{"key":"10.1016\/j.cmi.2025.06.003_bib30","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/00005792-198607000-00005","article-title":"Trichosporonosis in patients with neoplastic disease","volume":"65","author":"Walsh","year":"1986","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.cmi.2025.06.003_bib31","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1056\/NEJM195705302562202","article-title":"Pulmonary mucormycosis in acute histiocytic leukemia","volume":"256","author":"Stefanini","year":"1957","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2025.06.003_bib32","doi-asserted-by":"crossref","first-page":"345","DOI":"10.7326\/0003-4819-100-3-345","article-title":"Prolonged granulocytopenia: The major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia","volume":"100","author":"Gerson","year":"1984","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cmi.2025.06.003_bib33","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/0002-9343(78)90445-X","article-title":"Histoplasmosis in immunosuppressed patients","volume":"64","author":"Kauffman","year":"1978","journal-title":"Am J Med"},{"key":"10.1016\/j.cmi.2025.06.003_bib34","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1093\/ajcp\/79.4.509","article-title":"Disseminated histoplasmosis complicating bone marrow transplantation","volume":"79","author":"Walsh","year":"1983","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.cmi.2025.06.003_bib35","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1002\/1097-0142(197705)39:5<2265::AID-CNCR2820390546>3.0.CO;2-X","article-title":"Cryptococcosis in a cancer hospital: Clinical and pathological correlates in forty-six patients","volume":"39","author":"Kaplan","year":"1977","journal-title":"Cancer"},{"key":"10.1016\/j.cmi.2025.06.003_bib36","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/cncr.2820360612","article-title":"Intensity of immunosuppressive therapy and the incidence of Pneumocystis carinii pneumonitis","volume":"36","author":"Hughes","year":"1975","journal-title":"Cancer."},{"key":"10.1016\/j.cmi.2025.06.003_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000048465","article-title":"The challenge of invasive fungal infection","volume":"45","author":"De Pauw","year":"1999","journal-title":"Chemotherapy"},{"key":"10.1016\/j.cmi.2025.06.003_bib38","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/BF01967060","article-title":"Fungal infections in cancer patients: An international autopsy survey","volume":"11","author":"Bodey","year":"1992","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2025.06.003_bib39","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/ana.410180511","article-title":"Aspergillosis of the central nervous system: Clinicopathological analysis of 17 patients","volume":"18","author":"Walsh","year":"1985","journal-title":"Ann Neurol"},{"key":"10.1016\/j.cmi.2025.06.003_bib40","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/ajcp\/86.4.518","article-title":"The role of bronchoalveolar lavage in the diagnosis of invasive pulmonary aspergillosis","volume":"86","author":"Kahn","year":"1986","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.cmi.2025.06.003_bib41","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3390\/jof10100703","article-title":"Concordance of chest radiography and chest computed tomography findings in patients with hematologic malignancy and invasive Mucormycosis: What are the prognostic implications?","volume":"10","author":"Wurster","year":"2024","journal-title":"J Fungi (Basel)"},{"key":"10.1016\/j.cmi.2025.06.003_bib42","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1378\/chest.25.2.172","article-title":"Bronchiectasis due to asperigilloma","volume":"25","author":"Pesle","year":"1954","journal-title":"Dis Chest"},{"key":"10.1016\/j.cmi.2025.06.003_bib43","first-page":"115","article-title":"Pulmonary cavitation and massive hemoptysis in invasive pulmonary aspergillosis. Influence of bone marrow recovery in patients with acute leukemia","volume":"131","author":"Albelda","year":"1985","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.cmi.2025.06.003_bib44","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1148\/radiology.157.3.4059547","article-title":"Invasive pulmonary aspergillosis and acute leukemia. Limitations in the diagnostic utility of the air crescent sign","volume":"157","author":"Gefter","year":"1985","journal-title":"Radiology"},{"key":"10.1016\/j.cmi.2025.06.003_bib45","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/00004728-198705000-00033","article-title":"Radiologic-pathologic correlation of the CT halo sign in invasive pulmonary aspergillosis","volume":"11","author":"Hruban","year":"1987","journal-title":"J Comput Assist Tomogr"},{"key":"10.1016\/j.cmi.2025.06.003_bib46","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1007\/BF02276061","article-title":"Value of antigen and antibody detection in the serological diagnosis of invasive aspergillosis in patients with hematological malignancies","volume":"13","author":"Manso","year":"1994","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2025.06.003_bib47","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1093\/clinids\/6.3.301","article-title":"Current trends in immunodiagnosis of candidiasis and aspergillosis","volume":"6","author":"de Repentigny","year":"1984","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.cmi.2025.06.003_bib48","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/j.1399-3062.2003.00031.x","article-title":"Rapid diagnosis of invasive aspergillosis by antigen detection","volume":"5","author":"Wheat","year":"2003","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.cmi.2025.06.003_bib49","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/0003-4819-99-6-777","article-title":"Antigen detection in the diagnosis of invasive aspergillosis. Utility in controlled, blinded trials","volume":"99","author":"Weiner","year":"1983","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cmi.2025.06.003_bib50","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/0002-9343(82)90730-6","article-title":"Aspergillus antigen detection in bronchoalveolar lavage fluid from patients with invasive aspergillosis and aspergillomas","volume":"73","author":"Andrews","year":"1982","journal-title":"Am J Med"},{"key":"10.1016\/j.cmi.2025.06.003_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/infdis\/155.1.1","article-title":"Galactomannan antigenemia and antigenuria in aspergillosis: Studies in patients and experimentally infected rabbits","volume":"155","author":"Dupont","year":"1987","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2025.06.003_bib52","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0002-9343(82)90594-0","article-title":"Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia","volume":"72","author":"Pizzo","year":"1982","journal-title":"Am J Med"},{"key":"10.1016\/j.cmi.2025.06.003_bib53","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/0002-9343(89)90441-5","article-title":"Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group","volume":"86","year":"1989","journal-title":"Am J Med"},{"key":"10.1016\/j.cmi.2025.06.003_bib54","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","article-title":"Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group","volume":"340","author":"Walsh","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2025.06.003_bib55","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","article-title":"Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia","volume":"351","author":"Walsh","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2025.06.003_bib56","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1056\/NEJMe020142","article-title":"Echinocandins\u2014An advance in the primary treatment of invasive candidiasis","volume":"347","author":"Walsh","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2025.06.003_bib57","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/cid\/ciac623","article-title":"Empiric vs preemptive antifungal strategy in high-risk neutropenic patients on fluconazole prophylaxis: A randomized trial of the European Organization for Research and Treatment of Cancer","volume":"76","author":"Maertens","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.06.003_bib58","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1086\/597395","article-title":"Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: A randomized, controlled trial","volume":"48","author":"Cordonnier","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.06.003_bib59","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s10096-020-04054-9","article-title":"Clinical study on empirical and diagnostic-driven (pre-emptive) therapy of voriconazole in severe aplastic anaemia patients with invasive fungal disease after intensive immunosuppressive therapy","volume":"40","author":"Wu","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2025.06.003_bib60","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1001\/archinte.1958.00260230106014","article-title":"Experience with amphotericin B for the treatment of systemic mycoses","volume":"102","author":"Seabury","year":"1958","journal-title":"AMA Arch Intern Med"},{"key":"10.1016\/j.cmi.2025.06.003_bib61","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/j.1875-9114.1990.tb02593.x","article-title":"Prospective surveillance of intravenous amphotericin B use patterns","volume":"10","author":"Grasela","year":"1990","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cmi.2025.06.003_bib62","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1086\/313498","article-title":"Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis","volume":"29","author":"Wingard","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.06.003_bib63","doi-asserted-by":"crossref","first-page":"ii3","DOI":"10.1093\/jac\/dkac351","article-title":"Liposomal amphotericin B-the past","volume":"77","author":"Br\u00fcggemann","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.06.003_bib64","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/j.1875-9114.1984.tb03398.x","article-title":"Ketoconazole. Mechanism of action, spectrum of activity, pharmacokinetics, drug interactions, adverse reactions and therapeutic use","volume":"4","author":"Van Tyle","year":"1984","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cmi.2025.06.003_bib65","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/clinids\/2.4.535","article-title":"Criteria for evaluation of therapeutic response to antifungal drugs","volume":"2","author":"Dismukes","year":"1980","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.cmi.2025.06.003_bib66","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1086\/590566","article-title":"Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria","volume":"47","author":"Segal","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.06.003_bib67","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1086\/508455","article-title":"Issues related to the design and interpretation of clinical trials of salvage therapy for invasive mold infection","volume":"43","author":"Almyroudis","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.06.003_bib68","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.tmrv.2011.04.004","article-title":"Leukocyte transfusion and the development of the continuous-flow blood cell separator","volume":"25","author":"Freireich","year":"2011","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.cmi.2025.06.003_bib69","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/01.moh.0000190114.38650.b2","article-title":"Granulocyte transfusion","volume":"13","author":"Atallah","year":"2006","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.cmi.2025.06.003_bib70","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.3324\/haematol.2009.010231","article-title":"Granulocyte transfusions in severe aplastic anemia: An eleven-year experience","volume":"94","author":"Quillen","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.cmi.2025.06.003_bib71","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/jca.2920100406","article-title":"Collection and transfusion of granulocyte concentrates from donors primed with granulocyte stimulating factor and response of myelosuppressed patients with established infection","volume":"10","author":"Hester","year":"1995","journal-title":"J Clin Apher"},{"key":"10.1016\/j.cmi.2025.06.003_bib72","first-page":"351","article-title":"Implementation and outcomes of a transfusion-related acute lung injury surveillance programme and study of HLA\/HNA alloimmunisation in blood donors","volume":"10","author":"Porretti","year":"2012","journal-title":"Blood Transfus"},{"key":"10.1016\/j.cmi.2025.06.003_bib73","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.jcyt.2017.08.012","article-title":"Granulocyte transfusions: A concise review for practitioners","volume":"19","author":"Gea-Banacloche","year":"2017","journal-title":"Cytotherapy"},{"key":"10.1016\/j.cmi.2025.06.003_bib74","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1093\/clinids\/17.4.705","article-title":"Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer","volume":"17","author":"Bodey","year":"1993","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.06.003_bib75","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1086\/314047","article-title":"The use of adjuvant interferon-gamma therapy for hepatosplenic Blastoschizomyces capitatus infection in a patient with leukemia","volume":"31","author":"DeMaio","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.06.003_bib76","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac535","article-title":"Recombinant human granulocyte-macrophage colony-stimulating factor (rhu GM-CSF) as adjuvant therapy for invasive fungal diseases","volume":"9","author":"Chen","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2025.06.003_bib77","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1002\/1097-0142(19810515)47:10<2422::AID-CNCR2820471017>3.0.CO;2-Y","article-title":"Protected environment\u2014prophylactic antibiotic program for malignant sarcomas: Randomized trial during remission induction chemotherapy","volume":"47","author":"Bodey","year":"1981","journal-title":"Cancer."},{"key":"10.1016\/j.cmi.2025.06.003_bib78","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cmi.2025.06.003_bib79","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26711","article-title":"A randomized trial of the effectiveness of the neutropenic diet versus food safety guidelines on infection rate in pediatric oncology patients","volume":"65","author":"Moody","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.cmi.2025.06.003_bib80","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1080\/01635581.2015.1082109","article-title":"The effect of a neutropenic diet on infection and mortality rates in cancer patients: A meta-analysis","volume":"67","author":"Sonbol","year":"2015","journal-title":"Nutr Cancer"},{"key":"10.1016\/j.cmi.2025.06.003_bib81","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1128\/AAC.13.6.958","article-title":"Infection in acute leukemia patients receiving oral nonabsorable antibiotics","volume":"13","author":"Hahn","year":"1978","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.06.003_bib82","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/0030-4220(84)90128-2","article-title":"Evaluation of nystatin in prevention and elimination of oropharyngeal Candida in immunosuppressed patients","volume":"58","author":"Barrett","year":"1984","journal-title":"Oral Surg Oral Med Oral Pathol"},{"key":"10.1016\/j.cmi.2025.06.003_bib83","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1002\/1097-0142(19821215)50:12<2780::AID-CNCR2820501215>3.0.CO;2-P","article-title":"Candida infections in patients with acute leukemia: Ineffectiveness of nystatin prophylaxis and relationship between oropharyngeal and systemic candidiasis","volume":"50","author":"DeGregorio","year":"1982","journal-title":"Cancer"},{"key":"10.1016\/j.cmi.2025.06.003_bib84","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/jac\/31.6.973","article-title":"Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. Multicentre Study Group","volume":"31","author":"Philpott-Howard","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.06.003_bib85","first-page":"139","article-title":"Nystatin prophylaxis of fungal colonization and infection in granulocytopenic patients: Correlation of colonization and clinical outcome","volume":"8","author":"Buchanan","year":"1985","journal-title":"Clin Invest Med"},{"key":"10.1016\/j.cmi.2025.06.003_bib86","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002033","article-title":"Nystatin prophylaxis and treatment in severely immunodepressed patients","volume":"CD002033","author":"G\u00f8tzsche","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.cmi.2025.06.003_bib87","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1128\/AAC.2.6.423","article-title":"Clotrimazole (Bay b 5097): In vitro and clinical pharmacological studies","volume":"2","author":"Burgess","year":"1972","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.06.003_bib88","first-page":"1260","article-title":"Synthesen und Eigenschaften von Clotrimazol und weiteren antimykotischen 1-triphenylmethylimidazolen [Synthesis and properties of clotrimazole and other antimycotic 1-triphenylmethylimidazoles]","volume":"22","author":"B\u00fcchel","year":"1972","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.cmi.2025.06.003_bib89","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1200\/JCO.1985.3.12.1668","article-title":"Prophylaxis of oropharyngeal candidiasis with clotrimazole","volume":"3","author":"Yeo","year":"1985","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cmi.2025.06.003_bib90","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1182\/blood-2015-07-627323","article-title":"Primary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia","volume":"126","author":"Halpern","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2025.06.003_bib91","doi-asserted-by":"crossref","first-page":"617","DOI":"10.6004\/jnccn.2024.0056","article-title":"Prevention and treatment of cancer-related infections, version 3.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Baden","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.cmi.2025.06.003_bib92","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3324\/haematol.2010.030825","article-title":"Impact of invasive fungal disease on the chemotherapy schedule and event-free survival in acute leukemia patients who survived fungal disease: A case-control study","volume":"96","author":"Even","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.cmi.2025.06.003_bib93","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1086\/503844","article-title":"Clinical issues regarding relapsing aspergillosis and the efficacy of secondary antifungal prophylaxis in patients with hematological malignancies","volume":"42","author":"Sipsas","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.06.003_bib94","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1182\/blood.2020005884","article-title":"How I perform hematopoietic stem cell transplantation on patients with a history of invasive fungal disease","volume":"136","author":"Puerta-Alcalde","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.cmi.2025.06.003_bib95","doi-asserted-by":"crossref","first-page":"i19","DOI":"10.1093\/jac\/dkx030","article-title":"Early diagnosis of invasive mould infections and disease","volume":"72","author":"Lamoth","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.06.003_bib96","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1128\/JCM.00570-11","article-title":"Molecular detection and species-specific identification of medically important Aspergillus species by real-time PCR in experimental invasive pulmonary aspergillosis","volume":"49","author":"Walsh","year":"2011","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.cmi.2025.06.003_bib97","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1086\/323335","article-title":"Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An international consensus","volume":"34","author":"Ascioglu","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.06.003_bib98","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","volume":"46","author":"De Pauw","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.06.003_bib99","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and update of the consensus definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"Donnelly","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.06.003_bib100","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1080\/21505594.2016.1234566","article-title":"Risk stratification and immunogenetic risk for infections following stem cell transplantation","volume":"7","author":"W\u00f3jtowicz","year":"2016","journal-title":"Virulence"},{"key":"10.1016\/j.cmi.2025.06.003_bib101","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/cid\/cix687","article-title":"Call for Action: Invasive fungal infections associated with ibrutinib and other small molecule kinase inhibitors targeting immune signaling pathways","volume":"66","author":"Chamilos","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.06.003_bib102","doi-asserted-by":"crossref","first-page":"ofae133","DOI":"10.1093\/ofid\/ofae133","article-title":"The burden of invasive fungal disease following chimeric antigen receptor T-cell therapy and strategies for prevention","volume":"11","author":"Little","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2025.06.003_bib103","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jinf.2011.11.002","article-title":"Rare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancer","volume":"64","author":"Chitasombat","year":"2012","journal-title":"J Infect"},{"key":"10.1016\/j.cmi.2025.06.003_bib104","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01244-19","article-title":"Therapeutic challenges of non-Aspergillus invasive mold infections in immunosuppressed patients","volume":"63","author":"Lamoth","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.06.003_bib105","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.3201\/eid2111.150404","article-title":"Uncommon candida species fungemia among cancer patients, Houston, Texas, USA","volume":"21","author":"Jung","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.cmi.2025.06.003_bib106","doi-asserted-by":"crossref","first-page":"539","DOI":"10.7326\/0003-4819-86-5-539","article-title":"Treatment of invasive aspergillosis: Relation of early diagnosis and treatment to response","volume":"86","author":"Aisner","year":"1977","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cmi.2025.06.003_bib107","first-page":"1","article-title":"Diagnosis and management of invasive fungal diseases by next-generation sequencing: Are we there yet?","author":"Babady","year":"2024","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.cmi.2025.06.003_bib108","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/14737159.2019.1574572","article-title":"The expanding use of matrix-assisted laser desorption\/ionization-time of flight mass spectroscopy in the diagnosis of patients with mycotic diseases","volume":"19","author":"Walsh","year":"2019","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.cmi.2025.06.003_bib109","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1080\/14737159.2024.2397515","article-title":"Current and emerging technologies to develop Point-of-Care Diagnostics in medical mycology","volume":"24","author":"Matsuo","year":"2024","journal-title":"Expert Rev Mol Diagn"},{"key":"10.1016\/j.cmi.2025.06.003_bib110","doi-asserted-by":"crossref","first-page":"ofae257","DOI":"10.1093\/ofid\/ofae257","article-title":"Meeting the therapeutic challenges of emergent and rare invasive fungal diseases through novel clinical trial designs","volume":"11","author":"Walsh","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2025.06.003_bib111","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/myc.12167","article-title":"Our recommendations for avoiding exposure to fungi outside the hospital for patients with haematological cancers","volume":"57","author":"Ariza-Heredia","year":"2014","journal-title":"Mycoses"},{"key":"10.1016\/j.cmi.2025.06.003_bib112","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae226","article-title":"Shared vision for improving outcomes for serious fungal diseases: Report of a patient, caregiver, and clinician summit","volume":"11","author":"Purdie","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2025.06.003_bib113","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1018202","article-title":"Checkpoint inhibitors as immunotherapy for fungal infections: Promises, challenges, and unanswered questions","volume":"13","author":"Wurster","year":"2022","journal-title":"Front Immunol"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25002885?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X25002885?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T18:12:01Z","timestamp":1762366321000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X25002885"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":113,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1198743X25002885"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2025.06.003","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fungal infections in patients with haematological malignancies in the pre-triazole era: the dawn of a new era in medical mycology","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2025.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}